Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 (NASDAQ:ARCT)

Earnings Call InsightsArcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026Mar. 03, 2026 11:15 PM ETArcturus Therapeutics Holdings Inc. (ARCT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Management View CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose testing at 15 milligrams in 4Newslett ...